Anzeige
Meldung des Tages: Rohstoffstory der Spitzenklasse: Diese Abfolge haben die meisten Anleger noch nicht miteinander verbunden

Invesco Water Resources ETF Registered Shares News

ETF
WKN:  A2JNQQ ISIN:  US46137V1420 US-Symbol:  PHO
62,531 €
+1,99 $
+2,87%
62,531 € 19:16:44 Uhr
Depot/Watchlist
Indexbildung
Ertragsverwendung
-
Lfd. Kosten
-
Fondsgröße
-  
Tracking Error
-
Währung
FWW Fundstars
keine Bewertung

Invesco Water Resources ETF Registered Shares News

08.06.26 - PR Newswire
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer PR Newswire
08.06.26 - PR Newswire
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer PR Newswire
04.06.26 - PR Newswire
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics PR Newswire
04.06.26 - PR Newswire
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics PR Newswire
18.05.26 - PR Newswire
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study PR Newswire
18.05.26 - PR Newswire
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study PR Newswire
07.05.26 - PR Newswire
Photocure ASA: Results for the first quarter of 2026
Photocure ASA: Results for the first quarter of 2026 PR Newswire
07.05.26 - PR Newswire
Photocure ASA: Results for the first quarter of 2026
Photocure ASA: Results for the first quarter of 2026 PR Newswire
04.05.26 - PR Newswire
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
New health economic methodology published: comparing cost-​effectiveness of BLC versus NBI imaging technology in bladder cancer PR Newswire
04.05.26 - PR Newswire
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
New health economic methodology published: comparing cost-​effectiveness of BLC versus NBI imaging technology in bladder cancer PR Newswire
13.04.26 - PR Newswire
Photocure ASA: Update on Regulatory Classification for OAY Equipment
Photocure ASA: Update on Regulatory Classification for OAY Equipment PR Newswire
16.03.26 - PR Newswire
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway PR Newswire
16.03.26 - PR Newswire
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway PR Newswire
03.03.26 - PR Newswire
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Asieris: CEVIRA Approved in China as First-​in-Class Non-​Invasive Therapy for Cervical Precancerous Lesions PR Newswire
03.03.26 - PR Newswire
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Asieris: CEVIRA Approved in China as First-​in-Class Non-​Invasive Therapy for Cervical Precancerous Lesions PR Newswire
27.02.26 - PR Newswire
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe PR Newswire
18.02.26 - PR Newswire
Photocure ASA: Results for the fourth quarter of 2025
Photocure ASA: Results for the fourth quarter of 2025 PR Newswire
18.02.26 - PR Newswire
Photocure ASA: Results for the fourth quarter of 2025
Photocure ASA: Results for the fourth quarter of 2025 PR Newswire
08.12.25 - PR Newswire
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison PR Newswire
08.12.25 - PR Newswire
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison PR Newswire

Newssuche

Videos

newspaper
12:20 Uhr
INSIDER FLASH STRATEGY Einführung
Live-​Seminar am 2.8. ab 14 Uhr (Unterlagen und Aufzeichnung werden danach ausgehändigt). Vorab-... Mehr »